Hematology

Blincyto granted priority status to treat a form of acute lymphoblastic leukemia.

Animal model of malignant plasma-cell disease may accelerate new treatments for multiple myeloma.

Rapamycin may effectively treat patients with venous malformations.

The cost of oral cancer drugs spiked six-fold within the last 14 years.

Methotrexate and decadron could lower relapse rates of patients with acute lymphoblastic leukemia.

Medi-551 antibody targets the protein CD19 found on the surface of multiple myeloma stem cells.

Anti-CD38 monoclonal antibody daratumumab (Darzalex) shows promise for patients with multiple myeloma.

All-oral treatment regimen improves response rate in multiple myeloma.

Single-cell method identifies core stem cells that cause leukemia within a tumor.

The FDA has approved venetoclax (Venclexta) as a treatment for certain patients with chronic lymphocytic leukemia.

The FDA has approved venetoclax (Venclexta) as a treatment for certain patients with chronic lymphocytic leukemia.

Inhibiting GCN5 enzyme may lead to reduced remission risks and improved cure rates.

Venclexta is designed to trigger a natural process that helps cells self-destruct in chronic lymphocytic leukemia (CLL).

Venetoclax (Venclexta)is the first treatment approved by the FDA that inhibits the B-cell lymphoma 2 (BCL-2) protein.

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.

Experimental drug could may lead to new treatments for AML, lung cancer, brain cancer, and melanoma.

Approval of first oral proteasome inhibitor, ixazomib (Ninlato), may ease treatment burden for multiple myeloma.

A new pill makes all-oral therapy possible for patients with multiple myeloma.

Plitidepsin (Aplidin) in combination with dexamethasone found to reduce risk of progression and death from multiple myeloma.

Plitidepsin (Aplidin) in combination with dexamethasone shows 35% reduction in the risk of progression or death over comparator drug in multiple myeloma.

Research considers the importance of immunity in regulating the transformation from myelodysplastic syndrome to acute myeloid leukemia.

Stimulator of interferon gene agonists may offer hope in the treatment of in lymphoma, multiple myeloma, and certain forms of leukemia.

Promising study may lead to targeted treatment for patients with ALL.

Study estimates health insurers can save $9.1 million over 5 years per 100 CML patients.

Researchers seek to develop drugs that are less toxic and achieve longer remissions in multiple myeloma patients.